Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 16/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 11/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 11/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765941 | 0.90 | F2 (0.59) | F2PRSS1PRSS2PRSS3MCL1 | |
| SCHEMBL6767041 | 0.84 | TMPRSS6 (0.53) | F2PRSS1PRSS2PRSS3MCL1 | |
| SCHEMBL6764877 | 0.84 | F2 (0.57) | F2PRSS1PRSS2PRSS3MCL1 | |
| SCHEMBL6574363 | 0.83 | MCL1 (0.47) | F2PRSS1PRSS2PRSS3MCL1 | |
| SCHEMBL6771025 | 0.82 | F2 (0.55) | F2PRSS1PRSS2PRSS3MCL1 | |
| SCHEMBL6765424 | 0.82 | F2 (0.55) | F2PRSS1PRSS2PRSS3MCL1 | |
| SCHEMBL6765337 | 0.81 | F2 (0.52) | F2PRSS1PRSS2PRSS3MCL1 | |
| SCHEMBL6574434 | 0.78 | HTT (0.45) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6762119 | 0.78 | TMPRSS6 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL6574437 | 0.78 | ALDH1A1 (0.44) | F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | F2 612/4885PRSS1 1283/4885PRSS2 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.